Ketamine tested as Fast-Acting treatment for suicidal crisis
NCT ID NCT02299440
Summary
This study tested whether ketamine, given as an infusion, could provide rapid relief from suicidal thoughts in people hospitalized for suicide risk. In this Phase 3 trial, 156 participants were randomly assigned to receive either ketamine or a placebo to see which was more effective at reducing suicidal thoughts within 24 hours after treatment. The goal was to find a fast-acting option for a critical mental health emergency.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SUICIDAL IDEATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
APHP - Hôpital Lariboisière
Paris, 75010, France
-
CHRU de Lille - Hôpital Michel Fontan
Lille, 59037, France
-
CHRU de Montpellier - Hôpital Lapeyronie
Montpellier, 34295, France
-
CHRU de Nîmes - Hôpital Universitaire Carémeau
Nîmes, 30029, France
-
CHRU de Tours - Clinique Psychiatrique Universitaire
Saint-Cyr-sur-Loire, 37540, France
-
CHU de Clermont Ferrand - Hôpital Gabriel-Montpied
Clermont-Ferrand, 63003, France
-
CMME Centre Hospitalier Sainte Anne
Paris, 75674, France
-
Centre Hospitalier Sainte-Anne
Paris, 75674, France
-
Clinique Les Sophoras
Nîmes, 30000, France
Conditions
Explore the condition pages connected to this study.